A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of INV-101 Administered Orally to Healthy Adult Subjects
Latest Information Update: 09 May 2023
At a glance
- Drugs INV 101 Innovo Therapeutics (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors Innovo Therapeutics
Most Recent Events
- 09 May 2023 New trial record